Pulmonary Cell News Volume 4.42 | Oct 29 2015

Epigenetic Silencing of p21 by Long Non-Coding RNA HOTAIR Is Involved in the Cell Cycle Disorder Induced by Cigarette Smoke Extract
Scientists report that increased expression of Hox transcript antisense intergenic RNA (HOTAIR) and enhancer of zeste homolog 2, and tri-methylation of Lys 27 of histone H3, affect cell cycle progression during cigarette smoke extract-induced transformation of human bronchial epithelial cells. [Toxicol Lett] Abstract

Interleukin-17A and Toll-Like Receptor 3 Ligand Poly(I:C) Synergistically Induced Neutrophil Chemoattractant Production by Bronchial Epithelial Cells
Investigators assessed chemokine production by bronchial epithelial cells and investigated the underlying mechanisms. Comprehensive chemokine analysis showed that, compared with poly(I:C) alone, co-stimulation of BEAS-2B cells with interleukin-17A and poly(I:C) strongly induced production of such neutrophil chemoattractants as CXC chemokine ligand (CXCL)8, growth-related oncogene, and CXCL1. [PLoS One] Full Article

HO-1 Inhibits IL-13-Induced Goblet Cell Hyperplasia Associated with CLCA1 Suppression in Normal Human Bronchial Epithelial Cells
Researchers examined the effects of heme oxygenase-1 (HO-1) on mucin production and goblet cell hyperplasia induced by IL-13. Moreover, they assessed the cell signaling intermediates that appear to be responsible for mucin production. Normal human bronchial epithelial cells were grown at air liquid interface in the presence or absence of IL-13 and hemin, a HO-1 inducer, for 14 days. [Int Immunopharmacol] Abstract

LUNG CANCER

NLK Functions to Maintain Proliferation and Stemness of NSCLC and Is a Target of Metformin
Researchers investigated a novel role of Nemo-like kinase (NLK) and metformin in human non-small cell lung cancer (NSCLC). Lentivirus vectors with NLK-shRNA were used to examine the effect of NLK on cell proliferation and tumorigenesis in vitro. [J Hematol Oncol] Full Article

MARVELD1 Modulates Cell Surface Morphology and Suppresses Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer
The authors found MARVELD1 silencing altered cell surface ultrastructure of non-small cell lung cancer cells and inhibited the formation of punctate integrin β1/β4 cluster in microvillus, whereas MARVELD1 overexpression suppressed TGF-β1-induced epithelial–mesenchymal transition. [Mol Carcinog] Abstract

Overexpression of HPV16 E6/E7 Mediated HIF-1α Upregulation of GLUT1 Expression in Lung Cancer Cells
Investigators evaluated the underlying molecular mechanism that HPV16 regulate the expression of GLUT1 and may promote the development of lung cancer. HPV16, HIF-1α, and GLUT1 were detected in pleural effusions of patients with lung cancer and with benign lung disease by immunocytochemistry. [Tumor Biol] Abstract

Sanguiin H6 Suppresses TGF-β Induction of the Epithelial–Mesenchymal Transition and Inhibits Migration and Invasion in A549 Lung Cancer
To understand the inhibitory effects of sanguiin H6 on lung cancer migration and invasion, the authors investigated the ability of sanguiin H6 to inhibit transforming growth factor-beta 1 (TGF-β1)-induced epithelial–mesenchymal transition in the A549 cell line. [Bioorg Med Chem Lett] Abstract

HuR-Targeted Nanotherapy in Combination with AMD3100 Suppresses CXCR4 Expression, Cell Growth, Migration and Invasion in Lung Cancer
Scientists treated human H1299 lung cancer cells with HuR-specific siRNA contained in a folate-targeted lipid nanoparticle (HuR-FNP) plus AMD3100, and compared this with AMD3100 alone, HuR-FNP alone and no treatment. HuR-FNP plus AMD3100 treatment produced a G1 phase cell cycle arrest and reduced cell viability above and beyond the effects of AMD3100 alone. [Cancer Gene Ther] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

OrPro Therapeutics Receives US Patent Covering Novel Enzymatic Treatment for Cystic Fibrosis
OrPro Therapeutics, Inc. announced that the US Patent and Trademark Office has issued U.S. Patent No. 9,168,290 covering the ability of Theradux™ to improve the viscoelastic properties of mucus secretions in patients with diseases characterized by excessively viscous or cohesive mucus or sputum, such as cystic fibrosis and other obstructive lung diseases. [OrPro Therapeutics, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

Postdoctoral Position – Pulmonary Research (Helmholtz Association)

Postdoctoral Position – Lung Biology Research (University of Southern California)

Postdoctoral Fellowship – Developmental Cell Biology and Regenerative Medicine (University of California San Francisco)

Postdoctoral Researcher – Molecular Mechanisms of Pulmonary Diseases (Eastern Virginia Medical School)

Postdoctoral Fellow – Asthma (The University of Tennessee Health Science Center)

Postdoctoral Scholar – Autoimmune Diseases Affecting the Lung (University of California, San Francisco)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Research Fellow – Small Cell Lung Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.